Sanofi (NASDAQ:SNY) Sets New 1-Year Low – What’s Next?

Sanofi (NASDAQ:SNY)’s share price reached a new 52-week low on Tuesday. The stock traded as low as $39.18 and last traded at $39.2550, with a volume of 2,823,615 shares traded. The stock had previously closed at $39.74.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SNY shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. Royal Bank Of Canada assumed coverage on shares of Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Weiss Ratings upgraded Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. Finally, Wall Street Zen cut Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $49.50.

Sanofi Stock Down 1.2%

The company has a 50 day simple moving average of $42.93 and a two-hundred day simple moving average of $43.95. The company has a market capitalization of $95.22 billion, a P/E ratio of 20.56, a PEG ratio of 1.23 and a beta of 0.33. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.24 EPS. As a group, equities analysts predict that Sanofi will post 5.00 EPS for the current year.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently made changes to their positions in SNY. Avior Wealth Management LLC boosted its stake in Sanofi by 5.2% in the third quarter. Avior Wealth Management LLC now owns 6,412 shares of the company’s stock valued at $264,000 after acquiring an additional 319 shares in the last quarter. Sound Income Strategies LLC grew its stake in Sanofi by 1.6% during the 3rd quarter. Sound Income Strategies LLC now owns 92,404 shares of the company’s stock valued at $3,717,000 after purchasing an additional 1,447 shares during the last quarter. GAMMA Investing LLC increased its holdings in Sanofi by 32.3% in the 3rd quarter. GAMMA Investing LLC now owns 5,675 shares of the company’s stock worth $234,000 after buying an additional 1,386 shares during the period. Valeo Financial Advisors LLC raised its holdings in shares of Sanofi by 10.8% during the third quarter. Valeo Financial Advisors LLC now owns 6,346 shares of the company’s stock worth $262,000 after purchasing an additional 616 shares during the last quarter. Finally, Cooper Financial Group raised its stake in shares of Sanofi by 7.3% during the 3rd quarter. Cooper Financial Group now owns 6,935 shares of the company’s stock valued at $286,000 after buying an additional 471 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.